Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T72038
|
||||
| Former ID |
TTDR00804
|
||||
| Target Name |
Galectin-3
|
||||
| Gene Name |
LGALS3
|
||||
| Synonyms |
35 kDa lectin; Beta-galactoside-binding protein LGALS3; CBP 35; Carbohydrate binding protein 35; GALBP; Galactose-specific lectin 3; Galactoside-binding protein; IgE-binding protein; L-31; Laminin-binding protein; Lectin L-29; Mac-2 antigen; LGALS3
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Melanoma [ICD9: 172; ICD10: C43] | ||||
| Function |
Galactose-specific lectin which binds IgE. May mediate with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. Together with DMBT1, required for terminal differentiation of columnar epithelial cells during early embryogenesis (By similarity). In the nucleus: acts as a pre-mRNA splicing factor. Involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells.
|
||||
| UniProt ID | |||||
| Sequence |
MADNFSLHDALSGSGNPNPQGWPGAWGNQPAGAGGYPGASYPGAYPGQAPPGAYPGQAPP
GAYPGAPGAYPGAPAPGVYPGPPSGPGAYPSSGQPSATGAYPATGPYGAPAGPLIVPYNL PLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNN WGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDI DLTSASYTMI |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | GR-MD-02 | Drug Info | Phase 2 | Melanoma | [1] |
| Inhibitor | 2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide | Drug Info | [2] | ||
| GR-MD-02 | Drug Info | [3] | |||
| PFFFFF | Drug Info | [4] | |||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| Pathway Interaction Database | Hedgehog signaling events mediated by Gli proteins | ||||
| Regulation of Ras family activation | |||||
| Reactome | Advanced glycosylation endproduct receptor signaling | ||||
| WikiPathways | Spinal Cord Injury | ||||
| AGE/RAGE pathway | |||||
| Advanced glycosylation endproduct receptor signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02421094) Clinical Study for Non-Invasive Imaging Methods for GR-MD-02 for Treatment of Liver Fibrosis. U.S. National Institutes of Health. | ||||
| REF 2 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
| REF 3 | Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013 Dec 18;8(12):e83481. | ||||
| REF 4 | Bioorg Med Chem Lett. 2007 Feb 1;17(3):793-8. Epub 2006 Oct 27.Discovery of galectin ligands in fully randomized combinatorial one-bead-one-compound (glyco)peptide libraries. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.